Antares Pharma Given 5-Star Upgrade By Vetr

The Vetr community has upgraded Antares Pharma Inc. ATRS from 4 stars to 5 stars.

The stock has traded up a little under $1 year-to-date with its second-quarter earnings report coming up on August 8.

See how crowdsourced ratings can help predict the market?

Vetr members have given Antares Pharma a Strong Buy rating and a $3.18 price target. This price target is higher than the $3.10 price target from professional analysts. The stock opened Wednesday around $3.18.

Of all Vetr voters, 100 percent believe traders should buy Antares stock while none believe that traders should sell Antares stock.

For Vetr’s full analysis of Antares, go here.